Key facts
- Minerva Neurosciences established a scientific advisory board.
- The board will advance development of roluperidone and pipeline programs.
- Topline data from a 12-week Phase A trial is expected in 2H 2027.
Minerva Neurosciences is a biopharmaceutical company focused on developing treatments for central nervous system diseases. The establishment of a scientific advisory board is a common step to leverage external expertise for drug development and pipeline advancement.